Mesalamine

"Mesalamine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)

Descriptor ID	D019804
MeSH Number(s)	D02.241.223.100.050.300.500 D02.241.223.100.300.595.100.540 D02.241.511.390.595.100.540 D02.455.426.559.389.127.020.452.750 D02.455.426.559.389.127.281.595.100.540 D02.455.426.559.389.657.410.595.100.540
Concept/Terms	Mesalamine Mesalamine Mesalazine m-Aminosalicylic Acid m Aminosalicylic Acid 5-Aminosalicylic Acid 5 Aminosalicylic Acid meta-Aminosalicylic Acid meta Aminosalicylic Acid Asacol Asacol Asacolon Asacolon Ascolitin Ascolitin Canasa Canasa Claversal Claversal Fivasa Fivasa Salofalk Salofalk Lixacol Lixacol Mesalamine Hydrochloride Mesalamine Hydrochloride Hydrochloride, Mesalamine Mesalamine Monosodium Salt Mesalamine Monosodium Salt Monosodium Salt, Mesalamine Mesasal Mesasal Novo-5 ASA Novo-5 ASA Novo 5 ASA Pentasa Pentasa Rowasa Rowasa 5-Aminosalicylate 5-Aminosalicylate 5 Aminosalicylate

Below are MeSH descriptors whose meaning is more general than "Mesalamine".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Carboxylic Acids [D02.241]
Acids, Carbocyclic [D02.241.223]
Benzoates [D02.241.223.100]
Aminobenzoates [D02.241.223.100.050]
meta-Aminobenzoates [D02.241.223.100.050.300]
Mesalamine [D02.241.223.100.050.300.500]
Hydroxybenzoates [D02.241.223.100.300]
Salicylates [D02.241.223.100.300.595]
Aminosalicylic Acids [D02.241.223.100.300.595.100]
Mesalamine [D02.241.223.100.300.595.100.540]
Hydroxy Acids [D02.241.511]
Hydroxybenzoates [D02.241.511.390]
Salicylates [D02.241.511.390.595]
Aminosalicylic Acids [D02.241.511.390.595.100]
Mesalamine [D02.241.511.390.595.100.540]
Hydrocarbons [D02.455]
Hydrocarbons, Cyclic [D02.455.426]
Hydrocarbons, Aromatic [D02.455.426.559]
Benzene Derivatives [D02.455.426.559.389]
Benzoates [D02.455.426.559.389.127]
Aminobenzoates [D02.455.426.559.389.127.020]
meta-Aminobenzoates [D02.455.426.559.389.127.020.452]
Mesalamine [D02.455.426.559.389.127.020.452.750]
Hydroxybenzoates [D02.455.426.559.389.127.281]
Salicylates [D02.455.426.559.389.127.281.595]
Aminosalicylic Acids [D02.455.426.559.389.127.281.595.100]
Mesalamine [D02.455.426.559.389.127.281.595.100.540]
Phenols [D02.455.426.559.389.657]
Hydroxybenzoates [D02.455.426.559.389.657.410]
Salicylates [D02.455.426.559.389.657.410.595]
Aminosalicylic Acids [D02.455.426.559.389.657.410.595.100]
Mesalamine [D02.455.426.559.389.657.410.595.100.540]

Below are MeSH descriptors whose meaning is related to "Mesalamine".

Below are MeSH descriptors whose meaning is more specific than "Mesalamine".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Mesalamine" by people in this website by year, and whether "Mesalamine" was a major or minor topic of these publications.

Bar chart showing 10 publications over 8 distinct years, with a maximum of 2 publications in 2006 and 2018

To see the data from this visualization as text, click here.

Year	Major Topic	Total
2006	2	2
2007	1	1
2008	1	1
2009	1	1
2011	1	1
2013	1	1
2018	2	2
2019	1	1

Below are the most recent publications written about "Mesalamine" by people in Profiles.

Minacapelli CD, Bajpai M, Geng X, Van Gurp J, Poplin E, Amenta PS, Brant SR, Das KM. miR-206 as a Biomarker for Response to Mesalamine Treatment in Ulcerative Colitis. Inflamm Bowel Dis. 2019 01 01; 25(1):78-84.

View in: PubMed
Bajpai M, Seril DN, Van Gurp J, Geng X, Alvarez J, Minacapelli CD, Gorin S, Das KK, Poplin E, Cheng J, Amenta PS, Das KM. Effect of Long-Term Mesalamine Therapy on Cancer-Associated Gene Expression in Colonic Mucosa of Patients with Ulcerative Colitis. Dig Dis Sci. 2019 03; 64(3):740-750.

View in: PubMed
Parenti S, Montorsi L, Fantini S, Mammoli F, Gemelli C, Atene CG, Losi L, Frassineti C, Calabretta B, Tagliafico E, Ferrari S, Zanocco-Marani T, Grande A. KLF4 Mediates the Effect of 5-ASA on the ?-Catenin Pathway in Colon Cancer Cells. Cancer Prev Res (Phila). 2018 08; 11(8):503-510.

View in: PubMed
Chang WC, Zenser TV, Cooper HS, Clapper ML. Differential response of flat and polypoid colitis-associated colorectal neoplasias to chemopreventive agents and heterocyclic amines. Cancer Lett. 2013 Jun 28; 334(1):62-8.

View in: PubMed
Tursi A, Joseph RE, Streck P. Expanding applications: the potential usage of 5-aminosalicylic acid in diverticular disease. Dig Dis Sci. 2011 Nov; 56(11):3112-21.

View in: PubMed
Kamm MA, Lichtenstein GR, Sandborn WJ, Schreiber S, Lees K, Barrett K, Joseph R. Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis. Inflamm Bowel Dis. 2009 Jan; 15(1):1-8.

View in: PubMed
Clapper ML, Gary MA, Coudry RA, Litwin S, Chang WC, Devarajan K, Lubet RA, Cooper HS. 5-aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of azoxymethane/dextran sulfate sodium-induced colitis. Inflamm Bowel Dis. 2008 Oct; 14(10):1341-7.

View in: PubMed
Lichtenstein GR, Kamm MA, Boddu P, Gubergrits N, Lyne A, Butler T, Lees K, Joseph RE, Sandborn WJ. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2007 Jan; 5(1):95-102.

View in: PubMed
Kamm MA, Sandborn WJ, Gassull M, Schreiber S, Jackowski L, Butler T, Lyne A, Stephenson D, Palmen M, Joseph RE. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology. 2007 Jan; 132(1):66-75; quiz 432-3.

View in: PubMed
Kung SJ, Choudhary C, McGeady SJ, Cohn JR. Lack of cross-reactivity between 5-aminosalicylic acid-based drugs: a case report and review of the literature. Ann Allergy Asthma Immunol. 2006 Sep; 97(3):284-7.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement